DK1000079T3 - Hidtil ukendt formulering - Google Patents

Hidtil ukendt formulering

Info

Publication number
DK1000079T3
DK1000079T3 DK98934017T DK98934017T DK1000079T3 DK 1000079 T3 DK1000079 T3 DK 1000079T3 DK 98934017 T DK98934017 T DK 98934017T DK 98934017 T DK98934017 T DK 98934017T DK 1000079 T3 DK1000079 T3 DK 1000079T3
Authority
DK
Denmark
Prior art keywords
hitherto unknown
formulation
unknown formulation
hitherto
unknown
Prior art date
Application number
DK98934017T
Other languages
Danish (da)
English (en)
Inventor
Joanne Broadhead
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407718&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1000079(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of DK1000079T3 publication Critical patent/DK1000079T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DK98934017T 1997-07-11 1998-06-29 Hidtil ukendt formulering DK1000079T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9702680A SE9702680D0 (sv) 1997-07-11 1997-07-11 New formulation

Publications (1)

Publication Number Publication Date
DK1000079T3 true DK1000079T3 (da) 2006-11-20

Family

ID=20407718

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98934017T DK1000079T3 (da) 1997-07-11 1998-06-29 Hidtil ukendt formulering

Country Status (36)

Country Link
US (1) US6130208A (zh)
EP (1) EP1000079B1 (zh)
JP (1) JP4950380B2 (zh)
KR (1) KR100786654B1 (zh)
CN (2) CN1864696A (zh)
AR (1) AR013157A1 (zh)
AT (1) ATE340801T1 (zh)
AU (1) AU8362598A (zh)
BR (1) BR9810703A (zh)
CA (1) CA2295628C (zh)
CY (1) CY1105805T1 (zh)
CZ (1) CZ298110B6 (zh)
DE (1) DE69836023T2 (zh)
DK (1) DK1000079T3 (zh)
EE (1) EE04119B1 (zh)
ES (1) ES2273425T3 (zh)
HK (1) HK1026429A1 (zh)
HU (1) HU226489B1 (zh)
ID (1) ID24716A (zh)
IL (2) IL133868A0 (zh)
IS (1) IS2439B (zh)
MY (1) MY116421A (zh)
NO (1) NO329918B1 (zh)
NZ (1) NZ502073A (zh)
PL (1) PL192768B1 (zh)
PT (1) PT1000079E (zh)
RU (1) RU2216330C2 (zh)
SA (1) SA98190328B1 (zh)
SE (1) SE9702680D0 (zh)
SI (1) SI1000079T1 (zh)
SK (1) SK285766B6 (zh)
TR (1) TR200000006T2 (zh)
TW (1) TW585764B (zh)
UA (1) UA65576C2 (zh)
WO (1) WO1999002542A1 (zh)
ZA (1) ZA985669B (zh)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006038647A1 (ja) * 2004-10-05 2006-04-13 Asahi Kasei Pharma Corporation 補酵素の安定化方法およびその組成物
WO2009140092A1 (en) 2008-05-13 2009-11-19 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20120141468A1 (en) 2008-05-13 2012-06-07 Lisa Ruderman Chen Maintenance of platelet inhibition during antiplatelet therapy
US8759316B2 (en) 2008-05-13 2014-06-24 The Medicines Company Maintenance of platelet inhibition during antiplatelet therapy
US20130303477A1 (en) 2008-05-13 2013-11-14 The Medicines Company Maintenance of Platelet Inhibition During Antiplatelet Therapy
US9427448B2 (en) 2009-11-11 2016-08-30 The Medicines Company Methods of treating, reducing the incidence of, and/or preventing ischemic events
US9925265B2 (en) 2009-11-11 2018-03-27 Chiesi Farmaceutici S.P.A. Methods of treating or preventing stent thrombosis
US8729095B2 (en) 2009-08-28 2014-05-20 Daiichi Sankyo Company, Limited 3-(biaryloxy)propionic acid derivatives for prevention and/or treatment of thromboembolic diseases
US10376532B2 (en) 2009-11-11 2019-08-13 Chiesi Farmaceutici, S.P.A. Methods of treating, reducing the incidence of, and/or preventing ischemic events
MX2013006127A (es) * 2010-12-10 2013-09-26 Sigmapharm Lab Llc Composiciones sumamente estables de analogos nucleotidicoas oralmente activos o profarmacos analogos nucleotidicos oralmente activos.
CN103582480B (zh) 2011-02-09 2016-03-16 医药公司 治疗肺高压的方法
DK2744424T3 (en) 2011-08-17 2018-01-22 Samuel Shiber Adaptively rotating catheter to open clogged vessels in the body
ES2904256T3 (es) 2013-03-09 2022-04-04 Chiesi Farm Spa Métodos para tratar, reducir la incidencia de y/o prevenir eventos isquémicos
CN103772461A (zh) * 2014-01-06 2014-05-07 南京正科制药有限公司 一种坎格雷洛晶型ⅰ
BR112017014996A2 (pt) 2015-01-14 2018-03-20 Chiesi Farm Spa formulações farmacêuticas e recipientes selados
WO2018234565A1 (en) 2017-06-23 2018-12-27 Chiesi Farmaceutici S.P.A. METHOD FOR PREVENTING SHUNT THROMBOSIS FROM THE SYSTEMIC-PULMONARY ARTERY
CN112469710B (zh) 2018-06-19 2024-05-14 优时比制药有限公司 吡啶基及吡嗪基-（氮杂）吲哚磺酰胺

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5637967B2 (zh) * 1973-05-17 1981-09-03
JPS5874966A (ja) * 1981-10-28 1983-05-06 Mikuni Jukogyo Kk 高圧往復動機の軸封装置
JPS5874696A (ja) * 1981-10-30 1983-05-06 株式会社　ヤトロン アデノシン三リン酸の安定化方法
AU659645B2 (en) * 1991-06-26 1995-05-25 Inhale Therapeutic Systems Storage of materials
KR0131678B1 (ko) * 1991-12-09 1998-04-17 유미꾸라 레이이찌 파라티로이드 호르몬류의 안정화 조성물
DE69406649T2 (de) * 1993-02-10 1998-03-05 Astra Pharmaceuticals Ltd., Kings Langley, Hertfordshire N-alkyl-2-substituierte atp-analoge
RU2135176C1 (ru) * 1993-12-14 1999-08-27 Эли Лилли Энд Компани Водорастворенный комплекс включения соединений бензотиофена с водорастворимым циклодекстрином, способ его получения и фармацевтическая композиция
DE4405426A1 (de) * 1994-02-21 1995-08-24 Boehringer Mannheim Gmbh Pharmazeutisches Präparat enthaltend Plasminogenaktivator (t-PA) oder dessen Derivate
AU707734B2 (en) * 1995-06-07 1999-07-15 Regents Of The University Of California, The Stabilization of polynucleotide complexes
FR2740686B1 (fr) * 1995-11-03 1998-01-16 Sanofi Sa Formulation pharmaceutique lyophilisee stable
ID21635A (id) * 1996-12-20 1999-07-08 Astra Pharma Prod Komposisi farmasi untuk pengeringan beku

Also Published As

Publication number Publication date
PT1000079E (pt) 2006-12-29
CA2295628C (en) 2008-07-29
KR20010021647A (ko) 2001-03-15
PL337970A1 (en) 2000-09-11
SK285766B6 (sk) 2007-07-06
MY116421A (en) 2004-01-31
CY1105805T1 (el) 2011-02-02
SA98190328B1 (ar) 2006-08-15
EE200000022A (et) 2000-10-16
CZ298110B6 (cs) 2007-06-27
IL133868A0 (en) 2001-04-30
DE69836023D1 (de) 2006-11-09
SE9702680D0 (sv) 1997-07-11
EE04119B1 (et) 2003-08-15
HK1026429A1 (en) 2000-12-15
JP4950380B2 (ja) 2012-06-13
IS5331A (is) 1999-12-30
US6130208A (en) 2000-10-10
NO20000123L (no) 2000-03-03
CN1263533A (zh) 2000-08-16
KR100786654B1 (ko) 2007-12-21
UA65576C2 (uk) 2004-04-15
EP1000079A1 (en) 2000-05-17
PL192768B1 (pl) 2006-12-29
TR200000006T2 (tr) 2000-07-21
CZ200083A3 (cs) 2000-06-14
WO1999002542A1 (en) 1999-01-21
AU8362598A (en) 1999-02-08
HUP0002622A3 (en) 2002-04-29
DE69836023T2 (de) 2007-04-12
IL133868A (en) 2010-05-17
NZ502073A (en) 2001-09-28
IS2439B (is) 2008-11-15
ZA985669B (en) 1999-01-11
BR9810703A (pt) 2000-08-08
TW585764B (en) 2004-05-01
HUP0002622A2 (hu) 2001-05-28
ATE340801T1 (de) 2006-10-15
ES2273425T3 (es) 2007-05-01
HU226489B1 (en) 2009-03-02
RU2216330C2 (ru) 2003-11-20
CA2295628A1 (en) 1999-01-21
CN1864696A (zh) 2006-11-22
ID24716A (id) 2000-08-03
NO329918B1 (no) 2011-01-24
EP1000079B1 (en) 2006-09-27
NO20000123D0 (no) 2000-01-10
SI1000079T1 (sl) 2007-08-31
JP2001509512A (ja) 2001-07-24
SK183699A3 (en) 2000-07-11
AR013157A1 (es) 2000-12-13

Similar Documents

Publication Publication Date Title
ID25533A (id) Formulasi 2-metil-tieno-benzodiazepin
ID28698A (id) Formulasi antiparasit
ID29635A (id) Formulasi mikrokapsul
MA24473A1 (fr) Formulations
DE59810721D1 (de) Messfühler
DE59805163D1 (de) Messanordnung
DE59813698D1 (de) Trockenpartie
IS5118A (is) 2-amínó-6-(2-setinn-4-fenoxý)-setin-pýridín
NO20002126D0 (no) Formulering med forlenget frigjøring
DK1000079T3 (da) Hidtil ukendt formulering
ID27655A (id) Formulasi mikrokapsul
DK1029211T3 (da) Tørreindretning
IS5364A (is) Litarefni
DK0984952T3 (da) Hidtil ukendt salt
NO20002555L (no) Skjøt
DE69809184D1 (de) Kontaktmessfühler
ATE268607T1 (de) Allergenformulierung
FI973782A0 (fi) Linjefrekvenseffektkonverter fraon vaexelstroem till vaexelstroem
NO974904L (no) Måleinstrument
KR980000386U (ko) 손톱 착색용 기구
SE9800170D0 (sv) Formulation
SE9800766D0 (sv) Formulation
SE9803106D0 (sv) Novel formulation
UA25258A (uk) Вимірювальhа сигhалограма
DK125297A (da) Hidtil ukendt fremgangsmåde